May 11, 2015
The Pharmaceuticals and Medical Devices Agency (PMDA) announced on May 8 that crizotinib (product name: Xalkori), a treatment for non-small lung cancer, is being evaluated for the risk of cardiac failure. Certain safety measures such as the revision of the...read more